NVO
Novo Nordisk A/S
Healthcare · Drug Manufacturers - General · Denmark · Stock
Score Breakdown
Scored for Safe Long-Term Investing profile
Sub-scores are 0–20 each; Model Score is weighted by your selected investment goal. How it works →
Why Ranked Here
- Perfect scores in both profitability and financial health reflect genuinely exceptional fundamentals — elite margins, high asset returns, and a nearly debt-free balance sheet — that form the core of the 60.2/100 composite.
- A partial growth score reflects real but uneven expansion: 6.4% revenue growth was rewarded, but the much smaller 1.4% net income gain tempered the score.
- Below-midpoint scores in dividend and momentum, combined with a zero theme score, collectively weigh on the composite and prevent a higher overall ranking despite the strong fundamental foundation.
Why Not Higher
- The gap between revenue growth of 6.4% and net income growth of just 1.4% in FY2025 signals cost absorption or margin compression that limits the growth factor score.
- The theme assignment to Diabetes / GLP-1 / Metabolic Health scored zero under the current methodology, and the dividend factor remained below midpoint, both acting as structural drags on the composite.
Data Confidence
9 / 10
Very High — full data coverage
Why This Score
Grounded in figures from this company's SEC EDGAR filings — not a restatement of the score itself.
Revenue grew 6.4% from FY2024 to FY2025, while net income rose only 1.4% over the same period and diluted EPS increased 1.8% from FY2024 to FY2025.
The model appears to reward the top-line expansion but tempers the score given that earnings growth lagged revenue growth considerably, suggesting margin compression or rising costs absorbed much of the incremental revenue gain.
In FY2025, Novo Nordisk posted an operating margin of 41.3%, a net margin of 33.1%, and a return on assets of 18.9%.
These metrics reflect exceptional capital efficiency and pricing power; the model awarded a perfect score, consistent with margins and asset returns that rank among the highest in the pharmaceutical industry.
In FY2025, Novo Nordisk carried a debt-to-equity ratio of 0.05 and an interest coverage ratio of 18.8, against a total asset base of 542,902,000,000.
Near-zero financial leverage combined with an interest coverage ratio of 18.8x in FY2025 signals an exceptionally strong balance sheet, which the model rewarded with a perfect score.
Filing evidence currently available does not support a more specific explanation for this factor.
In FY2025, Novo Nordisk's dividend payout ratio stood at 50.5% of net income.
A payout ratio of 50.5% in FY2025 indicates the company returns a meaningful share of earnings to shareholders, but the model's below-midpoint score suggests it may also weigh dividend yield, growth rate, or consistency metrics that are not captured in the payout ratio alone.
Novo Nordisk is assigned to the Diabetes / GLP-1 / Metabolic Health macro themes.
Although the company is directly assigned to one of the most prominent current macro themes, this assignment did not translate into a positive score under the model's current methodology; the theme assignment itself remains a factual characteristic of the security regardless of the score outcome.
Research Summary
AI-generated analysis reflects data and conditions as of the report date shown above. Verify any specific figures through primary sources before acting on this analysis.
Novo Nordisk earns a composite score of 60.2/100 and is classified as a Core Holding Candidate with a Very Low risk rating, anchored by perfect scores in profitability and financial health. In FY2025, the company posted an operating margin of 41.3%, a net margin of 33.1%, and a return on assets of 18.9%, while carrying a near-zero debt-to-equity ratio of 0.05 and interest coverage of 18.8x. Revenue grew 6.4% year-over-year, though net income rose only 1.4%, indicating that rising costs or margin compression absorbed much of the incremental revenue gain. The composite score is tempered by below-midpoint scores in dividend and momentum factors, and the macro theme assignment to Diabetes / GLP-1 / Metabolic Health did not contribute positively under the model's current methodology.
Plain English
Novo Nordisk is an exceptionally profitable and financially solid pharmaceutical company — it barely carries any debt and keeps more than 33 cents of profit for every dollar of revenue — but its overall score is held back because earnings growth lagged revenue growth and some other scoring factors didn't add much.
Bull Case vs. Bear Case
Bull Case
- World-class profitability: an operating margin of 41.3% and net margin of 33.1% in FY2025 reflect strong pricing power and capital efficiency that rank among the highest in the pharmaceutical industry.
- Fortress balance sheet: a debt-to-equity ratio of just 0.05 and interest coverage of 18.8x in FY2025 mean the company carries virtually no financial leverage and can comfortably service any obligations.
- Consistent shareholder returns: a dividend payout ratio of 50.5% of net income in FY2025 shows the company returns a meaningful share of earnings to shareholders while retaining capital for operations.
Bear Case
- Earnings growth lagged revenue growth significantly: while revenue rose 6.4% from FY2024 to FY2025, net income grew only 1.4% over the same period, suggesting margin compression or rising costs are absorbing incremental revenue gains.
- Dividend score is below midpoint: the model's scoring suggests that payout ratio alone does not capture dividend yield, growth rate, or consistency, leaving this factor as a drag on the composite.
- Macro theme assignment did not contribute positively: despite being directly assigned to the prominent Diabetes / GLP-1 / Metabolic Health theme, this factor scored zero under the model's current methodology, weighing on the total score.
What Could Change the Picture
Bullish Triggers
- If future filings show net income growth converging toward or exceeding revenue growth, it would signal that cost pressures are easing and that the company's exceptional margins are being sustained or expanded.
- Evidence of accelerating dividend growth or a higher yield could improve the dividend factor score and lift the composite meaningfully.
Bearish Triggers
- A continued widening gap between revenue growth and net income growth — where costs persistently outpace top-line expansion — would signal structural margin erosion that could undermine the profitability pillar.
- Any deterioration in the near-zero leverage profile or a decline in interest coverage from the current 18.8x level would erode the financial health advantage that currently anchors the composite score.
Risk Profile
Very Low RiskNovo Nordisk carries a Very Low risk rating, supported by a debt-to-equity ratio of just 0.05 and an interest coverage ratio of 18.8x in FY2025, indicating the company has virtually no financial leverage and ample capacity to meet any debt obligations. The momentum factor score was produced by the model but lacks specific filing-based evidence to elaborate further on near-term risk dynamics.
This report is for educational and research purposes only. It does not constitute financial, investment, legal, or tax advice — always conduct your own due diligence before making investment decisions.